Riboflavin drives nucleotide biosynthesis and iron-sulfur metabolism to promote acute myeloid leukemia.
Saved in:
| Title: | Riboflavin drives nucleotide biosynthesis and iron-sulfur metabolism to promote acute myeloid leukemia. |
|---|---|
| Authors: | Bjelosevic S; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142 USA., Fauth R; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142 USA., Do BT; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142 USA.; Harvard-MIT Health Sciences and Technology, Cambridge, MA, 02142 USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, 02142 USA., Alexe G; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142 USA., Merickel LA; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142 USA., Jackson TD; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215 USA.; Department of Cell Biology, Harvard Medical School, Boston, MA, 02215 USA., Basanthakumar AT; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142 USA., Taillon A; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142 USA., Salhotra S; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142 USA., Ryback B; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215 USA., Schneider C; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142 USA., DiGiovanni G; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142 USA., Elbashir R; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142 USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, 02142 USA., Burger N; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215 USA.; Department of Cell Biology, Harvard Medical School, Boston, MA, 02215 USA., Bin Munim M; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142 USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, 02142 USA., Lin S; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142 USA., Puigserver P; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215 USA.; Department of Cell Biology, Harvard Medical School, Boston, MA, 02215 USA., Root DE; Broad Institute of MIT and Harvard, Cambridge, MA, 02142 USA., Vander Heiden MG; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142 USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, 02142 USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215 USA., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142 USA.; Lead contact. |
| Source: | BioRxiv : the preprint server for biology [bioRxiv] 2025 Jun 29. Date of Electronic Publication: 2025 Jun 29. |
| Publication Type: | Journal Article; Preprint |
| Journal Info: | Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
